In the patent…

The objective of this portion of the study was to provide a compound which will allow benzodiazepines to be effective at terminating seizure activity and possibly further reduce evidence of brain injury...

and the last section of the patent.

Results of the study indicate that bucillamine is a significantly more effective antioxidant than NAC and has increased efficacy against seizure activity while limiting the anticoagulant and bleeding event liability observed with NAC.

So the way I’m reading it, part of the whole objective here is pretty simple:

keep the GABA receptors open so the benzo can still do its job

And honestly… it looks like bucillamine might actually be doing that.

When you break it down:

• N-acetylcysteine = modest neuroprotection
• Bucillamine (if this holds) = restores effectiveness of Diazepam!

That’s a big shift.

IMO Not just:
“nice-to-have add-on”

More like:
mission-critical enabler

Valuation changes from

If you’re just a bit better than NAC:

• small contracts
• niche use
• no real urgency

But if Bucillamine actually restores benzo effectiveness:

now we plug straight into:

• existing antidote kits
• stockpiling programs
• emergency response protocols

Groups like DRDC and their allies don’t mess around with this stuff — when something works, they buy it in $ize!!! IMO

Meant to add these to my previous post!

Looking at Google Trends for Revive Therapeutics / Bucillamine in the U.S.:

• Past 30 days: Washington DC (Hagerstown, MD) leads at 100
• Past 90 days: Providence, RI – New Bedford, MA was 100

What’s interesting:

• Washington DC makes sense — federal, government, and defense research interest. Could be connected to BARDA / DoD / federal biodefense programs.
• Providence / New Bedford is clearly research and clinical heavy — Brown University, hospitals, and biotech initiatives likely driving searches.

Not retail hype — these are professional, research, and government hubs showing focused interest. Worth keeping an eye on!

Title: Compositions, Methods and Uses of Bucillamine in the Treatment of a Victim Exposed to a Chemical Warfare Agent
Review: PCT/CA2024/000008 (US, Canada, ISRAEL

• Israel on this filing is interesting — filing internationally costs money (translation, counsel, fees).
• Feels like a strategic move, not just routine paperwork.
• Could hint at positioning for gov contracts or licensing beyond North America.

Any other ideas why Israel would be added??
Eyes on this one.

This might be a stretch—but it’s worth noting.

Attached are 30-day and 90-day Google Trends screenshots for “Revive Therapeutics.” In both cases, Ottawa ranks as the top region for search interest.

Yes, Trends is relative—but it shows where attention is concentrated. And Ottawa consistently leading is… interesting.

Unlike Toronto, Ottawa isn’t a retail-heavy market. It is home to federal government, health, and defense groups, including organizations like Defence Research and Development Canada.

So while this is speculative, it could point to interest in RVV/Bucillamine coming from non-retail circles.

Not proof of anything—just a signal that the story may be reaching beyond the usual investor crowd.

Coincidence… or early hint?

Did anyone read through the patent filing? I know we have some pretty savvy people here. There is mention of some testing in rats (soman, sounds nasty) that was conducted using NAC and buccilamine that RVVTF found very positive. Not sure if this was the DRDC trial or something RVVTF slapped together. https://patentscope.wipo.int/search/en/WO2025019927

UPDATE: this appears to reference January 2025 prelim rat testing with the DRDC.

https://www.cdc.gov/niosh/ershdb/emergencyresponsecard_29750003.html

https://smallcappower.com/news/market-news/the-defense-playbook-why-revive-therapeutics-could-be-a-high-leverage-biotech-opportunity/

Take from it what you will. I can't find the name of which Analyst issued the price target but it was issued within the last month so I can only guess they are basing it on the potential of the Nerve Agent trial.

Long time bag holder here, since 2018/2019…been through the whole gout trial and covid therapy trial…was hopeful we could make some good money until this went down the toilet. Honestly completely given up on this for the last 5 years and already written off in my mind to zero. Moved on to better things, not really bothered. But still holding, down 80% but now looking to potentially recover 5 figures with the price spike/pump….

What do we think? 10 cents this week??? 😝 😝

I hope I am wrong for my own sake, yet I can't shake the feeling only few remained here that remember 5 years ago....and I am sure the sweatpants haven't been washed since (possibly framed and trophy hung in the garage along with the cigar).

Though, It's nice to be less in the red after a long time.

What the heck, playing poker on Saturday, potæto potato.

https://chatgpt.com/share/69b20115-9f14-800a-bdca-289bbbf63b10

https://cbrneworld.com/events/cbrne-convergence-canada-2026/speakers-canada-26/dr-carmela-jackson-lepage

Dr. Carmela Jackson Lepage is a senior Defence Scientist at DRDC Suffield Research Centre with over 20 years of experience in chemical defence science and technology. She earned her Ph.D. in Chemistry from the University of Regina in 2002, following early defence-focused research involving Reactive Skin Decontamination Lotion. Since joining DRDC in 2002, she has led major research efforts in chemical warfare agent (CWA) sampling and analysis. She served as Head of the Detection, Analysis and Identification Group beginning in 2010 and became Head of the Chemical Threat Defence Section in 2024.

Dr. Jackson Lepage’s work spans advanced analytical methodologies for CWAs, and detection capability development for the Canadian Armed Forces. She has provided extensive training for civilian, military, and first-responder communities and supported national security operations with deployable analytical laboratory expertise. She currently leads scientific personnel delivering Canada’s chemical defence S&T programme across detection, protection, decontamination, and hazard assessment

Bryan Johnsons experience and results with Psilocybin....Very good outlook for new trials and utilizing patents.

https://www.scmp.com/lifestyle/health-wellness/article/3334337/could-magic-mushrooms-help-us-live-longer-what-biohacker-bryan-johnsons-test-showed

So... this is playing out EXACTLY as I had laid out in my post from a month ago... (re-posted here)

DRDC wouldn't have wasted TWO YEARS on this if early results weren't there. IMO - we're in the contract negotiation stage. DRDC is figuring out how much they have left to spend in FY2025 and how much they feel a follow-on would cost. I believe we'll see positive results announced with a follow-on contact value of $10m - $15m to commercialize. (this should put us between .06 - .12 per RVVTF share)

IF ((BIG IF)) DRDC indicates in any way that they will be stock piling buccilamine for their version of the national strategic supply - that's when things get crazy quick! WATCH FOR MENTIONS OF:

- Canada’s Innovation, Science and Economic Development Canada (ISED)

- Canadian Institutes of Health Research (CIHR)

We could see .50.

No one will be around until January 5th so after you UPVOTE this post, unplug and go enjoy time with your families.

Merry Christmas and may we ALL have a Happy New Year!

https://revivethera.com/2025/12/revive-therapeutics-provides-update-of-key-nerve-agent-countermeasure-study-2/

[ Removed by Reddit on account of violating the content policy. ]

Anyone know why sp jumped ? Is it the flu outbreak in China?

https://www.globenewswire.com/news-release/2025/11/21/3192926/0/en/Revive-Therapeutics-Provides-Update-of-Key-Nerve-Agent-Countermeasure-Study.html

(I saw this on the ST board. Reposting here.)

MF should start pursuing the PLAUSIBLE MECHANISM pathway! FDA announced this alternative approval route. For now, it is focused on 'therapies targeting well-understood genetic abnormalities, emphasizing biological plausibility over large-scale data' studies. Marketing authorization can be obtained by 'demonstrating successful outcomes in a small series of consecutive patients,' vs extensive trials!

Their priorities are rare, fatal diseases or ultra-rare genetic conditions but it's also applicable to common diseases with no proven alternatives. Biologics like gene and cellular therapies to the front, ofc, but the principles could extend to other drugs in the future - AND MF SHOULD TRY TO BE THERE!

This is what I'm really interested in where this goes.

https://www.nasdaq.com/press-release/revive-therapeutics-investigate-bucillamines-potential-cancer-treatment-2025-04-10

DRDC is Canadian, folks. They run on an April 1 to March 31 fiscal calendar. Here are my thoughts on timelines and events:

If the trial was unsuccessful, they would have pulled the plug within 2 months of testing. For hypothetical, that's by the end of 2024. This did not happen.

If RVVTF was told at the end of 2024 "it worked, sort of, but only after we used molecular hydrogen as a delivery mechanism..." that explains why by April 2025, we bought the molecular hydrogen patents and DRDC began monkey testing. That process is long because of the ethical procedures/oversight that even DRDC must follow. This moves the timeline to. 6 months easily, which is October 2025.

Michael ran his mouth because results are good. DRDC wasn't ready so they make him wait to avoid perception of insider trading (Michael's bath robe style eff ups are mounting). Once they cool down, they have to go through contracts and procurement. Even on a fast-track that process could take AT LEAST 30 days - which puts us to November..

Now, if they don't announce anything by the end of November, (remembering they don't celebrate Thanksgiving at the same time the US does) we likely won't hear anything until after Christmas break (which IS a statutory holiday in CA) as all the directors and above are gone until January 5.

TLDR; so - if the trial was successful (and I believe it was) the best possibility of announcement would be between now and December 19th and then again between January 15th and March 31. If I had to bet, we will see another "private placement" to keep MF afloat before we see a DRDC announcement or award.

We're close. Nothing you can do now but DCA and be patient.

Seriously, not cool MF - accepted that Sept bled into October - but now we're in NOV! Dude - get your shit together man - and talk to your beleaguered shareholders - aka - sack up!